Clinical Trial Update: PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children [Phase 2]

View source ↗

Summary

Phase II study of everolimus in pediatric patients with recurrent or progressive low-grade gliomas has completed enrollment with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low-grade Glioma

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: University of California, San Francisco | Conditions: Pediatric Recurrent Progressive Low-grade Gliomas, Pediatric Progressive Low-grade Gliomas | Phase 2 | Status: COMPLETED | Results posted: 2021-02-18